The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California.
The CANVAS study’s outcomes were “a positive first step” in proving that canagliflozin can be used for the primary prevention of heart failure in patients with diabetes, but more evidence is needed, according to the study’s lead author, Bruce Neal, MB, ChB, PhD, of the George Institute for Global Health at UNSW Sydney, who presented the findings at the 77th Scientific Sessions of the American Diabetes Association’s in San Diego, California.
Transcript (slightly modified)
How was the CANVAS program different from other SGLT2 inhibitor trials?
It’s hard to directly compare the CANVAS program with the other SGLT2 programs because we’ve got a slightly different patient subset. For example, two-thirds of our patients were patients with existing vascular disease, but one-third were primary prevention patients, so that’s a new patient subset that’s being investigated here, but that makes it difficult to directly compare it to the others.
I think the top line is that, if you look at the CANVAS program compared to the Jardiance program, for that primary cardiovascular outcome the findings are almost identical. Once you start to get down into looking at more specific outcomes with smaller numbers of events, it’s really much harder to make robust comparisons.
What do the CANVAS results indicate about primary prevention of heart failure with canagliflozin?
The program results are interesting, because we did have this one-third of participants who were primary prevention. Of course, we don’t have enough events to say this was independently significant in primary prevention because we didn’t power it to do that. What we can do is look to see, was there any evidence that it was different in the primary prevention to the secondary prevention, and we certainly don’t see any evidence of that. It’s a positive first step, but we really want some more data.
In terms of the heart failure piece, I think there’s a lot of interest in this class for the management of heart failure, because it clearly has a volume offloading effect, and that’s probably a big part of why we see these early benefits with the drug. I think patients who have got diabetes and are perceived to be at risk of heart failure are going to be really strong candidates for canagliflozin and other SGLT2 inhibitors.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Intermountain Healthcare and Story Health Partner to Optimize Rural Heart Failure Care
February 7th 2023On this episode of Managed Care Cast, we speak with Tom Stanis, CEO and cofounder of Story Health, and Phillip Wood, Intermountain Ventures program director, on how their partnership came about, how it is going so far, and the future of their collaboration.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More